Graft-Versus-Host Disease Clinical Trial
Official title:
The Experience of Having Chronic Graft-Versus-Host Disease
Primary Objectives:
1. To explore the experience of chronic graft-versus-host disease (cGVHD) following
allogeneic blood or marrow transplantation from the perspective of the patient and the
patient's primary family caregiver.
2. To develop and validate an instrument to measure the severity of multiple symptoms and
the impact of these symptoms on daily functioning in patients who have cGVHD.
Secondary Objectives:
1. To develop a detailed description of the experience of having cGVHD.
2. To develop a detailed description of the symptom experience of cGVHD to allow for
development of a symptoms instrument for cGVHD.
3. To assess the understanding of questions to measure the symptoms of cGVHD in patients
with various levels of education.
4. To develop a detailed description of caring for a patient with cGVHD.
For Patient:
If you agree to take part in this study, you will be asked to take part in 1 interview.
During the interview, you will be asked to describe what it has been like for you to have
chronic GVHD. In addition, if you agree to take part in this study, your family caregiver,
if you have one, will be approached to take part in the study.
For Caregiver:
If you agree to take part in this study, you will be asked to take part in 1 interview.
During the interview, you will be asked to describe what it has been like for you to help
care for a family member with chronic GVHD.
Both Parties:
The interview face-to-face will take place while you are at M. D. Anderson receiving care.
You will be interviewed alone and the information gathered during the interview will be
strictly confidential. The interview will take about 30 minutes and will be tape recorded.
The audiotape of the interview will be kept in a locked cabinet in the office of the study
chairperson Dr. Loretta Williams. If other study personnel need the tape for analysis, they
must obtain the tape directly from Dr. Williams. They may keep the tape only while they are
listening to it and must return it immediately to Dr. Williams. Identification labels on the
tape will only contain your study number and will not contain your name, medical record
number, or other identifying information. When all analysis for the study has been completed
and reported, the audiotape will be destroyed.
After the interview, you will be asked to answer a face-to-face questionnaire. This
questionnaire will ask descriptive personal information (age, marital status, etc.).
Answering these questions should take about 5 minutes.
Your participation on this study ends after you complete the interview and questionnaire.
This is an investigational study. About 20 patients and 20 caregivers will take part in this
study. All will be enrolled at M. D. Anderson.
For Patient - Phase III:
If you agree to take part in this study, you will be asked to complete 1 questionnaire. The
questionnaire will have questions asking you to rate how severe your current symptoms are
and how much these symptoms disrupt your daily activities. You will be asked to complete
this questionnaire during your clinic visit. The questionnaire will take no more than 10
minutes to complete.
If you have chronic graft-versus-host disease, you will be asked to complete a second
questionnaire about your opinion of the symptom questionnaire (the first questionnaire). For
example, you will be asked if the symptom questionnaire was easy to understand and to
complete. Learning your opinion about this questionnaire will help researchers learn what
important questions may be missing from the questionnaire. The questionnaire will take no
more than 10 minutes to complete.
If you have chronic graft-versus-host disease, you will also be given questions asking you
to rate the overall quality of your life and your ability to function. These ratings should
take no more than 2 minutes to complete.
Finally, you will be asked to answer a questionnaire. This questionnaire will ask
descriptive personal information (such as age and marital status). Answering these questions
should take about 5 minutes.
If you have chronic GVHD, you may be asked to fill out the questionnaire rating your
symptoms 1 more time, about 3 days after you completed it the first time. You will return
this second questionnaire to the research staff in a pre-addressed, stamped envelope given
to you by the research staff. If you are asked to complete the questionnaire this second
time, the research staff will also ask for your telephone number so that they may contact
you and remind you to complete the questionnaire.
Identification labels on all study questionnaires and forms will only contain your study
number and will not contain your name, medical record number, or other identifying
information. All study materials will be kept in a locked cabinet at all times. When all
analysis for the study has been completed and reported, the questionnaires will be
destroyed.
The study ends when you have completed the questionnaires, rating scales, and interview in
the clinic, or when you have completed and returned the second questionnaire 3 days after
your clinic visit.
This is an investigational study. Up to 192 patients will take part in this study. 147 will
be enrolled at M. D. Anderson and 45 will be enrolled at Roswell Park Cancer Institute.
;
Time Perspective: Prospective
Status | Clinical Trial | Phase | |
---|---|---|---|
Active, not recruiting |
NCT01428973 -
Minitransplants With HLA-matched Donors : Comparison Between 2 GVHD Prophylaxis Regimens
|
Phase 2 | |
Not yet recruiting |
NCT00749164 -
Allogeneic Mesenchymal Stem Cell for Graft-Versus-Host Disease Treatment
|
Phase 1/Phase 2 | |
Completed |
NCT00993343 -
Randomized Trial Comparing Sirolimus and Tacrolimus Versus Cyclosporine and Methotrexate as Graft-versus-host Disease (GVHD) Prophylaxis After Allogeneic Stem Cell Transplantation
|
Phase 3 | |
Completed |
NCT00360685 -
Tacrolimus and Mycophenolate Mofetil (MMF) in GVHD Prophylactic Regimen Compared to Tacrolimus and Methotrexate (MTX
|
N/A | |
Active, not recruiting |
NCT04503616 -
Cyclophosphamide, Abatacept, and Tacrolimus for GvHD Prevention
|
Phase 1/Phase 2 | |
Terminated |
NCT02080195 -
Nonmyeloablative Conditioning and Transplantation for Patients With Refractory Systemic Lupus Erythematosus (SLE)
|
Phase 1/Phase 2 | |
Completed |
NCT02193880 -
Safety of Post-transplant Alpha-beta Depleted T-cell Infusion Following Haploidentical Stem Cell Transplant (Haplo SCT)
|
N/A | |
Completed |
NCT02942173 -
CD45RA Depleted T-cell Infusion for Prevention of Infections After TCRab/CD19-depleted Allo-HSCT
|
Phase 2/Phase 3 | |
Completed |
NCT02145403 -
Phase 1/2 Study of Carfilzomib for the Prevention of Relapse and GVHD in Allo-HCT for Hematologic Malignancies
|
Phase 1/Phase 2 | |
Recruiting |
NCT01941394 -
Mesenchymal Stem Cells Infusion for aGVHD Prophylaxis Transplantation
|
Phase 2 | |
Completed |
NCT00141713 -
The Use of Etanercept (Enbrel®) in the Treatment of Acute Graft-Versus-Host Disease
|
Phase 2 | |
Recruiting |
NCT01991301 -
Carfilzomib for the Prevention of Graft Versus Host Disease
|
Phase 1 | |
Completed |
NCT00408928 -
Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease
|
Phase 2 | |
Completed |
NCT01633229 -
Bone Marrow Stromal Cell Infusions for Stem Cell Transplant Complications
|
Phase 1 | |
Completed |
NCT05856058 -
To Assess SHR0302 Oral Solutions and Tablets in Healthy Subjects Clinical Studies of Relative Bioavailability
|
Phase 1 | |
Completed |
NCT02342613 -
Adoptive Immunotherapy With Activated Marrow Infiltrating Lymphocytes and Cyclophosphamide Graft-Versus-Host Disease Prophylaxis in Patients With Relapse of Hematologic Malignancies After Allogeneic Hematopoietic Cell Transplantation
|
Phase 1 | |
Recruiting |
NCT06423131 -
Prospective Clinical Trial for Children With TCRαβ Depleted vs Traditional Haplo Identicle HSCT
|
N/A | |
Completed |
NCT02144025 -
Prevention of Ocular Graft-Versus-Host Disease With Topical Cyclosporine in Recipients of Allogeneic HSCT
|
Phase 2 | |
Completed |
NCT01369914 -
The Natural History of Graft-Versus-Host Disease in the Eyes
|
||
Completed |
NCT00806728 -
Study of MEDI-507 in With Steroid-Resistant Acute Graft-Versus-Host Disease
|
Phase 1 |